4894.TCuorips Inc.
The schedule
- Wed20Jan
Update on Cuorips' U.S. subsidiary, iReheart, and FDA IND clearance for initiating clinical trials of the iPSC cardiomyocyte sheets in the United States.
- Fri12Feb
Fiscal Q3 earnings print, expected to show an acceleration in RiHEART domestic sales as more designated cardiac centers complete their first commercial procedures.
- Fri14May
- Tue18May
Presentation of initial post-marketing real-world data on RiHEART, a critical requirement under Japan's conditional regenerative medicine regulatory pathway.
- Fri13Aug
- Fri12Nov
Past
- Tue15Sep
Actual outcome: Mixed · $5,640.00 at outcome
The stock closed at $5640 on the outcome date, surpassing the bear floor and moving toward the bull target. The event focused on the launch of RiHEART Commercial and NHI coverage, which signaled strong strategic momentum and long-term growth potential. Despite a potential earnings miss, the positive guidance and expansion into new markets drove the rally, aligning with the bull case.
Effective September 1, RiHEART secures National Health Insurance reimbursement at JPY 53.2 million, transitioning Cuorips into its commercial phase. Early market penetration will test the real-world logistics for these allogeneic iPSC patches.